Deep Vein Thrombosis Clinical Trial
Official title:
The Cesarean Section Thromboprophylaxis Pilot Study:A Randomized Open-Label Controlled Pilot Study of Prophylactic Low Molecular Weight Heparin in High Risk Postpartum Women Following Cesarean Section
Verified date | February 2018 |
Source | Ottawa Hospital Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Venous thromboembolism (VTE) remains the most common cause of maternal death in the developed
world. VTE includes two conditions, deep vein thrombosis (DVT) and pulmonary embolism (PE).
DVT refers to a blood clot that has formed in a deep vein, often in the legs and/or pelvis
and PE refers to the passage of these clots into the lungs (which can be fatal). VTE is up to
10 times more common in pregnant women than non-pregnant women of comparable age. More than a
third of pregnancy related VTE occur during the 6 weeks after delivery. When compared with
vaginal delivery, cesarean delivery further increases the risk of pregnancy associated VTE by
three-fold.
A medication called low molecular weight heparin is sometimes prescribed during pregnancy and
after delivery to prevent VTE. However, clinical practice varies because there hasn't been
adequate research to determine that this medication is safe and effective at preventing VTE
during this time. The potential benefits of the medication must also be weighed against its
cost and possible side effects.
The researchers are conducting a study that will assess the effectiveness and safety of low
molecular weight heparin in women who are at moderate to high risk of VTE after a cesarean
section. They will monitor these women to determine if those who received the medication have
fewer blood clots. Participants will also be monitored closely for any side effects.
Status | Completed |
Enrollment | 30 |
Est. completion date | September 2006 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria (must meet inclusion criteria 1, 2 and 3): 1. At high risk for thromboembolism (any one of the following): 1. Age > 35 years 2. Obesity (> 80 kg) 3. Para 4 4. Gross varicose veins 5. Current infection 6. Pre-eclampsia 7. Immobility prior to surgery (> 4 days) 8. Major current disease: includes heart or lung disease, cancer, inflammatory bowel disease, and nephrotic syndrome. 9. Emergency cesarean section in labour 10. Extended major pelvic or abdominal surgery (e.g. cesarean hysterectomy) 11. Patients with a family history of VTE 12. History of superficial phlebitis 2. Delivered by cesarean section (emergency or planned) 3. Signed, informed consent Exclusion Criteria (must not meet any of the following criteria): 1. Greater than 36 hours since delivery 2. Need for anticoagulation, including: 1. Women with a confirmed thrombophilia 2. Women with paralysis of lower limbs 3. Women with personal history of VTE 4. Women with antiphospholipid antibody syndrome (APLA) 5. Women with mechanical heart valves 3. Contraindication to heparin therapy, including: 1. History of heparin induced thrombocytopenia 2. Platelet count of less than 100,000 x 10^6/L 3. Hemoglobin <= 90 g/L or a greater than 30 g/L drop in hemoglobin compared to last antepartum result 4. History of osteoporosis 5. History of steroid use (one week or more) 6. Active bleeding 7. Documented peptic ulcer within 6 weeks 8. Heparin, bisulfite, or fish allergy 9. Severe hypertension (systolic blood pressure [SBP] > 200 and/or diastolic blood pressure [DBP] > 120) 10. Severe hepatic failure (International Normalized Ratio [INR] > 1.8) 11. Women with serum creatinine > 80 and an abnormal 24 hour creatinine clearance. 4. Contraindications to magnetic resonance imaging (MRI), including: 1. Women with electrically, magnetically or mechanically activated implants 2. Women with claustrophobia 5. Women < 18 years of age |
Country | Name | City | State |
---|---|---|---|
Canada | Ottawa Hospital | Ottawa | Ontario |
Lead Sponsor | Collaborator |
---|---|
Ottawa Hospital Research Institute | LEO Pharma |
Canada,
Rodger MA, Avruch LI, Howley HE, Olivier A, Walker MC. Pelvic magnetic resonance venography reveals high rate of pelvic vein thrombosis after cesarean section. Am J Obstet Gynecol. 2006 Feb;194(2):436-7. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | VTE on magnetic resonance venography (MRV) or bilateral leg Doppler ultrasound |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05003843 -
BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis
|
N/A | |
Recruiting |
NCT03937947 -
Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
|
||
Withdrawn |
NCT04136561 -
Novel Strategy to Encourage Early Removal of Central Venous Catheters
|
N/A | |
Completed |
NCT03420625 -
Blood Flow Stimulation in the Lower Limbs by Application of Different External Devices
|
N/A | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Completed |
NCT02555111 -
Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.
|
Phase 3 | |
Terminated |
NCT02469376 -
Evaluation of a New Imagingtechnologie for Thrombosis
|
Phase 1 | |
Completed |
NCT01975090 -
The SENTRY Clinical Study
|
N/A | |
Completed |
NCT02037607 -
Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures
|
N/A | |
Not yet recruiting |
NCT01357941 -
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
|
N/A | |
Completed |
NCT00773448 -
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
|
N/A | |
Completed |
NCT00771303 -
Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
|
||
Completed |
NCT00720915 -
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
|
N/A | |
Completed |
NCT00244725 -
Odiparcil For The Prevention Of Venous Thromboembolism
|
Phase 2 | |
Completed |
NCT00264277 -
D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism
|
Phase 4 | |
Completed |
NCT00365950 -
3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE
|
Phase 4 | |
Completed |
NCT00182403 -
Fixed Dose Heparin Study
|
Phase 3 | |
Completed |
NCT03682419 -
Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)
|
N/A | |
Not yet recruiting |
NCT04981327 -
The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis
|
Phase 3 | |
Recruiting |
NCT03240120 -
A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism
|
Phase 3 |